Lynparza (olaparib)

pCPA File Number: 21464
Negotiation Status:
Active Negotiation
Indication(s):
Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
PC0223-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable